新辅助卡培他滨治疗可手术HPV阴性头颈癌:资源有限环境下的偶然发现
前瞻性队列研究比较2周期新辅助卡培他滨(NC)与标准治疗(SC)在可手术HPV阴性头颈鳞癌中的临床-病理分期迁移,NC组16例、SC组32例;NC组10例出现病理缓解,分期迁移分布与SC组显著不同(P=0.0047),无严重治疗毒性。
要点
- NC组10例出现病理缓解(1例完全、3例主要、6例次要)。
- 临床-病理分期迁移:NC组降期6例、升期3例、无变化7例;SC组降期1例、升期14例、无变化17例(P=0.0047)。
- 无与卡培他滨相关的严重治疗毒性,NC组全部患者均接受手术。
核心结论
- 新辅助卡培他滨后手术在HPV阴性头颈鳞癌中显示可测量的病理缓解,提示在资源有限的医疗环境中可能有用。
研究设计与样本
- 前瞻性队列研究,比较接受新辅助卡培他滨(NC)的患者与按部位和TNM分期匹配的接受标准治疗(SC)的患者。
- 研究在加拿大蒙特利尔2个学术中心进行。
- NC组16例(11例口腔、3例皮肤、2例喉),SC组32例。
- 评估2周期NC对可手术HPV阴性头颈鳞癌临床-病理分期迁移的影响。
- 病理治疗反应采用改良Ryan评分测量。
主要发现
- NC组16例中10例出现病理缓解(1例完全、3例主要、6例次要)。
- 临床-病理分期迁移在NC组与SC组间差异显著:降期6例 vs 1例,升期3例 vs 14例,无变化7例 vs 17例(P=0.0047)。
- 无与卡培他滨相关的严重治疗毒性。
- NC组所有患者均接受手术。
临床怎么用
- 作者认为,新辅助卡培他滨后手术在HPV阴性头颈鳞癌中显示可测量的病理缓解,提示在资源有限的医疗环境中可能有用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Limited progress has occurred in treating operable human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). Accessing timely care remains challenging in public health care systems, potentially resulting in disease progression before treatment initiation. STUDY DESIGN: A prospective cohort of patients receiving neoadjuvant capecitabine (NC) was compared to stage-matched patients undergoing standard of care (SC). SETTING: This study was performed at 2 academic centers in Montreal, Canada. METHODS: To ascertain the effect of 2 cycles of NC in operable HPV-negative HNSCC patients on clinical-to-pathologic stage migration. Comparison to an SC group was performed to site and TNM stage matched patients. Pathologic treatment response was measured using the modified Ryan score. RESULTS: We compared 16 NC patients (11 oral cavity, 3 skin, 2 larynx) with 32 SC patients. Ten NC patients exhibited a pathologic response (1 complete, 3 major, 6 minor). Clinical-to-pathologic stage migration differed significantly between NC and SC groups: downstage (6 vs 1), upstage (3 vs 14), no change (7 vs 17, P = .0047). There was no severe treatment toxicity related to capecitabine. All patients in the NC group underwent surgery. CONCLUSION: NC followed by surgery demonstrates measurable pathologic response in HPV-negative HNSCC, suggesting potential utility in resource-limited health care settings.
引用
- Mascarella MA, Richardson K, Mlynarek A, et al. Neoadjuvant Capecitabine in Operable HPV-Negative Head and Neck Cancer: Fortuitous Findings in a Resource Constrained Setting. Otolaryngol Head Neck Surg. 2024. PMID: 39342503. doi:10.1002/ohn.1003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。